Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Liquidity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Merck & Co. Inc., liquidity ratios (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Current ratio
Quick ratio
Cash ratio

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


Current Ratio
The current ratio demonstrates a generally stable to slightly increasing trend over the observed period. Beginning at 1.11 in March 2020, it rises to a peak of 1.47 by December 2022, indicating improved short-term liquidity during this time. Thereafter, it fluctuates moderately, with values between 1.25 and 1.47, maintaining a position above 1, which suggests the company consistently held a comfortable ability to meet its short-term liabilities.
Quick Ratio
The quick ratio mirrors the general upward trend seen in the current ratio but remains lower throughout the period. Starting from 0.66 in March 2020, it increases steadily to reach a peak of 0.93 in December 2022, indicating an enhancement in liquid assets relative to current liabilities. Following this peak, the quick ratio experiences some volatility, declining to as low as 0.68 in June 2023 and December 2023 before rising again towards 0.88 by September 2024. This pattern points to some fluctuations in the company's more immediate liquidity position, though it remains below the current ratio, reflecting the exclusion of inventory from liquid assets.
Cash Ratio
The cash ratio remains the most conservative liquidity measure and exhibits more pronounced variability. Starting at 0.32 in March 2020, it increases to 0.54 in December 2022, indicating a strengthening cash position relative to current liabilities over this timeframe. Post this peak, the ratio decreases gradually, reaching lows near 0.22 in June 2024, followed by moderate recoveries up to approximately 0.49 by September 2024. These fluctuations highlight changes in cash and cash equivalents that are more volatile but generally suggest that the company maintained a moderate cash buffer relative to its short-term obligations throughout the period.
Overall Liquidity Analysis
Across all three liquidity ratios, there is evidence of an overall strengthening in the company's ability to cover short-term liabilities from March 2020 through late 2022, likely reflecting operational improvements or strategic liquidity management. Post-2022, the variations in these ratios imply more dynamic cash and asset management, with temporary reductions in liquidity measures likely due to operational or investment activities, followed by recoveries. Despite this, the ratios consistently remain above critical thresholds, indicating a maintained capacity to meet short-term financial obligations.

Current Ratio

Merck & Co. Inc., current ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The data reveals fluctuations in the company's liquidity position over the observed quarters, as represented primarily by current assets, current liabilities, and the current ratio.

Current Assets
Current assets displayed an overall increasing trend from March 31, 2020 (26,174 million USD) to December 31, 2022 (35,722 million USD). Following this peak, there was a dip through mid to late 2023, where the value decreased to approximately 29,977 million USD by June 30, 2023. After this decline, current assets recovered strongly into early 2024, reaching their highest value of 40,361 million USD by June 30, 2024. Subsequently, a decline ensued, with current assets decreasing to 35,503 million USD by March 31, 2025.
Current Liabilities
Current liabilities began at 23,483 million USD on March 31, 2020 and experienced moderate variability throughout the period. They dropped to a low of 20,405 million USD on September 30, 2020, then sharply increased to 27,327 million USD by December 31, 2020. Afterward, liabilities fluctuated within the 22,000 to 26,000 million USD range, peaking at 29,586 million USD on September 30, 2024. The latest available figure was slightly lower at 25,174 million USD by March 31, 2025.
Current Ratio
The current ratio, indicative of short-term liquidity, experienced a moderate range of fluctuations. Initially, it increased from 1.11 at March 31, 2020 to 1.32 by June 30, 2020, followed by a dip to 1.02 at December 31, 2020 and March 31, 2021. From mid-2021 through 2022 and into early 2023, the current ratio maintained a stronger level mostly between 1.25 and 1.47, reflecting a healthier liquidity position. In mid-2023, it briefly declined to 1.25 but rebounded to 1.47 by June 30, 2024. The period ended with a stable current ratio near 1.40, implying the company consistently held current assets above current liabilities, with some volatility within comfortable liquidity levels.

Overall, there is evidence that the company managed to grow its current assets at a pace generally exceeding the growth in current liabilities, which supported improvements in liquidity ratios over the long term. Short-term declines and recoveries indicate periods of working capital adjustment, but the current ratio staying above 1.0 throughout implies the company maintained an adequate capability to meet short-term obligations during the entire period.


Quick Ratio

Merck & Co. Inc., quick ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Accounts receivable, net of allowance for doubtful accounts
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


Total Quick Assets
The total quick assets show a fluctuating pattern over the observed periods. Starting at 15,614 million USD in March 2020, the value increased to a peak of 22,642 million USD by December 2022. However, this peak was followed by a decline to 17,408 million USD in June 2023, before another upward adjustment reaching 25,974 million USD in June 2024. In the most recent data point, March 2025, total quick assets decreased to 20,018 million USD. Overall, the trend indicates volatility with periods of growth followed by corrections.
Current Liabilities
Current liabilities have demonstrated considerable variation throughout the timeline. From an initial value of 23,483 million USD at the start of 2020, there was a notable drop to 20,405 million USD by September 2020, followed by a sharp increase to 27,327 million USD at the end of 2020. After this spike, liabilities fluctuated moderately within the 22,000 to 29,500 million USD range. The highest observed liability reached near 29,586 million USD in September 2024. By March 2025, the liabilities reported a decline to 25,174 million USD. This pattern suggests periods of increased short-term obligations interspersed with moderate reductions.
Quick Ratio
The quick ratio, representing liquidity, reveals a generally low but improving position with fluctuations. The ratio started at 0.66 in March 2020, increased to 0.84 in June 2020, then declined to its lowest point of 0.58 in December 2020 and March 2021. It subsequently improved steadily, reaching a high of 0.93 in December 2022. However, a decline followed to 0.68 by June 2024, with a partial recovery to 0.88 in September 2024. The last data point reports a quick ratio of 0.80 in March 2025. The overall trend demonstrates a company managing fluctuating liquidity, with improvements in several periods but occasional dips, indicating variable ability to cover short-term liabilities with liquid assets.

Cash Ratio

Merck & Co. Inc., cash ratio calculation (quarterly data)

Microsoft Excel
Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The financial data indicates fluctuating levels of cash assets and current liabilities over the observed periods, with corresponding variations in the cash ratio. The analysis focuses on identifying key trends and changes across these metrics.

Total cash assets
Cash assets exhibit significant variability without a clear upward or downward long-term trend. Starting at 7,432 million US dollars at the beginning of 2020, the figure reaches a high of 13,192 million by the end of 2022. However, this peak is followed by notable declines and recoveries, with the lowest point observed at 5,619 million in the first half of 2024 before rebounding to above 14,000 million later that same year. The data suggests periods of cash accumulation interspersed with drawdowns, reflecting potentially varying liquidity needs or cash management strategies.
Current liabilities
Current liabilities remain comparatively stable but display a modest upward trend over time. Beginning at 23,483 million US dollars in early 2020, liabilities fluctuate slightly but primarily increase, peaking around 29,586 million in the third quarter of 2024. Thereafter, there is a marginal decline to 25,174 million. The general rise in liabilities may indicate increased short-term obligations or operational scaling.
Cash ratio
The cash ratio — measuring the company's liquidity position through cash assets relative to current liabilities — shows considerable volatility. Early 2020 starts with a relatively low ratio of 0.32, with a peak of 0.54 in late 2022. Following this peak, there is a decline into the 0.22-0.28 range in early to mid-2024, before improving again towards 0.49 by late 2024. This variation implies fluctuating liquidity coverage, likely influenced by the dynamics of cash and current liabilities.

Overall, the data suggest a company managing liquidity actively, with cash assets and liquidity ratios responding dynamically to changing liabilities. Peaks in cash assets and the cash ratio indicate short periods of stronger liquidity, while troughs may reflect increased cash usage or investment activity. Current liabilities show a mild growth trend, which may imply expanding operational or short-term financial commitments over the observed periods.